Although the results of clinical studies suggest that PD-L1 expression and TMB—important biomarkers of the response to ICIs [25]—do not predict clinical benefit from ICIs in patients with SCLC, there is some evidence that PD-L1 expression has potential for use as a biomarker [22,26]. Here, CD274 is linked to small cell lung carcinoma.